196 related articles for article (PubMed ID: 6128460)
1. Basal ganglia disease.
Marsden CD
Lancet; 1982 Nov; 2(8308):1141-7. PubMed ID: 6128460
[No Abstract] [Full Text] [Related]
2. The role of anticholinergic drugs in extra-pyramidal syndromes.
Hunter KR
Neuropharmacology; 1981 Dec; 20(12B):1315-7. PubMed ID: 6119641
[No Abstract] [Full Text] [Related]
3. [Neurotransmitters, drugs and neuropsychiatric diseases (author's transl)].
Relja M; Lackvoić Z
Lijec Vjesn; 1979 Oct; 101(10):609-16. PubMed ID: 44538
[No Abstract] [Full Text] [Related]
4. [Drug therapy of parkinsonism].
Teräväinen H; Larsen TA
Duodecim; 1982; 98(11):892-900. PubMed ID: 6125373
[No Abstract] [Full Text] [Related]
5. Assessment of extrapyramidal disorders.
Marsden CD; Schachter M
Br J Clin Pharmacol; 1981 Feb; 11(2):129-51. PubMed ID: 6452152
[No Abstract] [Full Text] [Related]
6. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders.
Crossman AR
Neuroscience; 1987 Apr; 21(1):1-40. PubMed ID: 2955248
[No Abstract] [Full Text] [Related]
7. Therapeutics of disordered movement.
Sears ES
Am Fam Physician; 1977 Sep; 16(3):145-54. PubMed ID: 143204
[TBL] [Abstract][Full Text] [Related]
8. The neuropharmacology of tardive dyskinesia, spontaneous dyskinesia, and other dystonias.
Stahl SM; Davis KL; Berger PA
J Clin Psychopharmacol; 1982 Oct; 2(5):321-8. PubMed ID: 6127351
[TBL] [Abstract][Full Text] [Related]
9. Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters.
Meldrum B
Clin Sci (Lond); 1985 Feb; 68(2):113-22. PubMed ID: 2857118
[No Abstract] [Full Text] [Related]
10. Serotonin and Parkinson's disease.
Hesselink JM
Am J Psychiatry; 1993 May; 150(5):843-4. PubMed ID: 8480847
[No Abstract] [Full Text] [Related]
11. [GABA and diseases of the extrapyramidal system].
Carrieri P
Acta Neurol (Napoli); 1977; 32(5):697-704. PubMed ID: 22223
[No Abstract] [Full Text] [Related]
12. Basal Ganglia dysfunctions in movement disorders: What can be learned from computational simulations.
Schroll H; Hamker FH
Mov Disord; 2016 Nov; 31(11):1591-1601. PubMed ID: 27393040
[TBL] [Abstract][Full Text] [Related]
13. Involuntary movement disorders.
Still CN
Neurol Clin; 1984 Feb; 2(1):71-89. PubMed ID: 6239089
[TBL] [Abstract][Full Text] [Related]
14. [Basal ganglia lesions and neurotransmitters].
Yoshida M
Nihon Rinsho; 1978; 36(1):58-64. PubMed ID: 24766
[No Abstract] [Full Text] [Related]
15. The pharmacology of extrapyramidal movement disorders.
Klawans HL
Monogr Neural Sci; 1973; 2():1-136. PubMed ID: 4271860
[No Abstract] [Full Text] [Related]
16. CRH defects in Alzheimer's and other neurologic diseases.
de Souza EB
Hosp Pract (Off Ed); 1988 Sep; 23(9):59-71. PubMed ID: 2901426
[No Abstract] [Full Text] [Related]
17. Current views on Parkinson's disease.
Calne DB
Can J Neurol Sci; 1983 Feb; 10(1):11-5. PubMed ID: 6132677
[TBL] [Abstract][Full Text] [Related]
18. Amantadine.
Parkes D
Adv Drug Res; 1974; 8():11-81. PubMed ID: 4219097
[No Abstract] [Full Text] [Related]
19. The role of basal ganglia in rhythmic movement.
Freund HJ; Hefter H
Adv Neurol; 1993; 60():88-92. PubMed ID: 8420222
[No Abstract] [Full Text] [Related]
20. Neuropharmacology of degenerative diseases associated with aging.
Growdon JH
Med Res Rev; 1983; 3(3):237-57. PubMed ID: 6136638
[No Abstract] [Full Text] [Related]
[Next] [New Search]
